Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review
Oncology Research · 2026 · 34 (6) · 1-10
DOI: 10.32604/or.2026.076300 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research, 2026. Verfasst von Guoliang Zhong und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, China. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, China.
- Department of Breast Surgery, Dongguan People's Hospital, Dongguan, China.
Zitieren
APA
Zhong, G., Yang, T., Lin, S., & Zhong, M. (2026). Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review. Oncology Research, 34(6), 1-10. https://doi.org/10.32604/or.2026.076300
Vancouver
Zhong G, Yang T, Lin S, Zhong M. Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review. Oncology Research. 2026;34(6):1-10. doi:10.32604/or.2026.076300
BibTeX
@article{Zhong2026,
author = {Zhong, Guoliang and Yang, Tianqing and Lin, Shuqi and Zhong, Muyi},
title = {Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review},
journal = {Oncology Research},
year = {2026},
volume = {34},
number = {6},
pages = {1--10},
doi = {10.32604/or.2026.076300}
}
EUVIMED